C4 Therapeutics (CCCC) Receivables (2019 - 2026)
C4 Therapeutics (CCCC) posted quarterly Receivables of $2.9 million for Q1 2026, down 64.09% year-over-year from $8.0 million in Q1 2025, and up 20.07% quarter-over-quarter from $2.4 million in Q4 2025.
C4 Therapeutics (CCCC) Receivables (2019 - 2026) Analysis & Trends
C4 Therapeutics' Receivables history runs 8 years deep, the most recent figure standing at $2.9 million for Q1 2026.
- In Q1 2026, Receivables fell 64.09% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (down 64.09% YoY), while the FY2025 annual figure was $2.4 million, down 22.6% from the prior year.
- Receivables for Q1 2026 stood at $2.9 million, up from $2.4 million in the prior quarter.
- The five-year high for Receivables was $13.6 million in Q1 2024, with the low at $500000.0 in Q3 2023.
- The 5-year median for Receivables is $2.2 million (2025), against an average of $4.1 million.
- The sharpest annual moves came in 2022 and 2024: Receivables sank 74.23% in 2022, then surged 2475.57% in 2024.
- C4 Therapeutics' Receivables stood at $1.5 million in 2022, then surged by 701.02% to $11.8 million in 2023, then plunged by 73.71% to $3.1 million in 2024, then fell by 22.6% to $2.4 million in 2025, then climbed by 20.07% to $2.9 million in 2026.
- Business Quant data shows CCCC's Receivables at $2.9 million in Q1 2026, $2.4 million in Q4 2025, and $6.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - | 1.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.33 Mn |
| Mar 31, 2026 | 2.88 Mn |
| Dec 31, 2025 | 2.40 Mn |
| Sep 30, 2025 | 6.54 Mn |
| Jun 30, 2025 | 2.16 Mn |
| Mar 31, 2025 | 8.03 Mn |
| Dec 31, 2024 | 3.10 Mn |
| Sep 30, 2024 | 10.34 Mn |
| Jun 30, 2024 | 1.17 Mn |
| Mar 31, 2024 | 13.60 Mn |
| Dec 31, 2023 | 11.80 Mn |
| Sep 30, 2023 | 500,000.00 |
| Jun 30, 2023 | 1.03 Mn |
| Mar 31, 2023 | 528,000.00 |
| Dec 31, 2022 | 1.47 Mn |
| Sep 30, 2022 | 1.49 Mn |
| Jun 30, 2022 | 1.71 Mn |
| Mar 31, 2022 | 1.77 Mn |
| Dec 31, 2021 | 5.72 Mn |
| Sep 30, 2021 | 4.85 Mn |